These results demonstrate that RHOB prevents erlotinib‐induced AKT dephosphorylation, suggesting that the RHOB/AKT axis might account for the sensitivity of EGFR‐mutated tumor cells to EGFR‐TKI treatment. This evidence concerns the gene AKT1 and neoplasm.